Orionis Biosciences

The company's platforms—Allo-Glue™, A-Kine®, and multimodal cell engagers—work by connecting proteins on and within cells to target cancer through the body's natural defense mechanisms. Orionis focuses on precision targeting to harness immune signaling while minimizing off-target effects.